Related Experiment Video
Updated: Jun 12, 2026
04:09
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film
Published on: December 13, 2024
Controlled release formulation of ranitidine-containing montmorillonite and Eudragit E-100
Ghanshyam V Joshi1, Bhavesh D Kevadiya, Hari C Bajaj
1Discipline of Inorganic Materials and Catalysis, Central Salt and Marine Chemicals Research Institute, Council of Scientific and Industrial Research (CSIR), Bhavnagar, Gujarat, India.
Drug Development and Industrial Pharmacy
|June 16, 2010
Summary
Montmorillonite (MMT) serves as a promising drug delivery carrier for ranitidine hydrochloride (RT). Polymer coating with Eudragit E-100 enhanced RT release from the MMT-RT composite.
Area of Science:
- Materials Science
- Pharmaceutical Sciences
- Nanotechnology
Background:
- Montmorillonite (MMT) is a clay mineral with potential applications in drug delivery.
- Ranitidine hydrochloride (RT) is a widely used medication for acid reflux and ulcers.
Purpose of the Study:
- To develop and characterize a novel clay-drug composite using MMT and RT.
- To investigate the drug release profile of the MMT-RT composite, with and without Eudragit E-100 coating.
Main Methods:
- Ion-exchange process to prepare the MMT-RT composite.
- X-ray diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) for structural analysis.
- In vitro release studies in simulated gastric fluid.
Main Results:
- XRD and FTIR confirmed successful intercalation of RT within MMT interlayers.
- MMT-RT composite exhibited controlled release of RT.
- Eudragit E-100 coating significantly increased both the rate and extent of RT release.
- Release kinetics followed a parabolic diffusion mechanism.
Conclusions:
- MMT is a viable carrier for drug delivery applications.
- The MMT-RT/Eudragit E-100 microparticles show potential for tablet formulation.
- Polymer coating can modulate drug release from clay-based composites.
Related Concept Videos
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...